



AOGS BULLETIN

www.ahmedabadobgyn.org

AHMEDABAD OBSTETRICS AND GYNAECOLOGICAL SOCIETY NEWS LETTER

JUNE 2013

Theme :
Knock the "t" off the can't



◆ **President**
Dr. Mahesh Gupta
+91 94264 99922
m99922g@yahoo.com

◆ **Hon. Secretary**
Dr. Phagun Shah
+91 98254 31233
phagunshah@gmail.com

◆ **President - Elect**
Dr. Dilip Gadhavi
98980 47505

◆ **Vice President**
Dr. Kiran Desai
98250 87144

◆ **Treasurer**
Dr. Anil Mehta
+91 98253 16970

◆ **Jt. Secretary**
Dr. Jignesh Deliwala
+91 98250 44819

◆ **Managing Committee**

Dr. Anjana Chauhan
Dr. Archana Shah
Dr. Geetendra Sharma
Dr. Kalpesh Trivedi

Dr. Kamini Patel
Dr. Kaushik Vyas
Dr. Mukesh Patel
Dr. Sunil Shah

◆ **Ex-Officio**

Dr. Dipesh Dholakiya
Dr. Hemant Bhatt



Editor's message

Dear Friends,
Season's greetings!

Many of you must be relaxing or enjoying vacation at domestic or international tourist places with friends & family. Some may be preparing for the career of their kin's as result season is also going on. Hearty congratulations to the children of AOGSsians who passed with flying colors.

Friends, at AOGS, Team AOGS is busy planning & organizing CMEs, workshops & family entertainment programs under the vibrant leadership of the President Dr. Mahesh Gupta & Hon. Secretary Dr. Phagun Shah.

First time in the history of AOGS & AMA a joint program was organized on Gynec Update on 19th may 2013 at hotel Metropole. The program was well attended by 174 delegates of both the organizations. The program was inaugurated by Dr. Harshad Shah, president of All India Radiologist Association & Dr. Jitubhai Patel, ex MLA & President elect of IMA (Headquarter). The program was very well organized & well executed. Kudos to coordinators Dr. Kiran Desai & Dr. Jignesh Shah (A.M.A).

On the same day i.e. 19th may, the first of many surgical workshops planned in the different areas of Ahmedabad during the year to enhance the surgical skills & capacity to tackle the emergencies effectively by our members was organized at Anand Surgical Hospital, Bapunagar. Thirty Five members attended the workshop. It was a grand success. Congratulations to Dr. Mukesh Savalia & Dr. Mukesh Patel for successfully organizing the workshop. If any member wants to organize such workshop in their area please contact Dr. Mukesh Savalia.

The same enthusiasm of first two months of the new year continues in June & July. On 2nd June a laparoscopy conference is organized in association with IAGE at Hotel St. Lourn. A surgical demonstration workshop on cadaver is organized on 17th June at V.S. hospital. Perhaps first time in the history of AOGS. Please register immediately at AOGS office for the workshop as limited seats are available.

Above all "**JARA HATKE**" family entertainment program is planned on the evening of **Sunday, 7th July** with Bumper Housie & Gala Dinner. Prizes worth more than 1,00,000 Rupees to be won. So please gear up for the program.

A midterm SOGOG conference organized by AOGS in association with Udaipur society is held at Sheraton, Udaipur, on **3rd & 4th August, 2013.**

So friends be charged. Don't let the sadness of your past & your fear of the future ruin your happiness today. Stay positive because today could be the best day of your life.

Editorial team, AOGS

Workshop On Cadaveric Dissection



Venue: Cadaveric Lab,
VS Hospital, Ahmedabad.

Date : 17th June 2013, Monday

Registration Fees : Rs. 1000/-

Co-ordinators : Dr. Mukesh Savalia,
Dr. Kalpesh Trivedi

Hall Co-ordinator : Dr. Kiran Desai

Program Details

Time	Subject
09.00 am to 09.30 am	Breakfast
09.30 am to 10.00 am	Inauguration
10.00 am to 02.00 pm	Demonstration of :
	(a) TOT & Obturator foramen anatomy - Dr. Vineet Mishra
	(b) Perineal Anatomy - Dr. Ajit Rawal
	(c) Posterior Compartment of Pelvis - Dr. Mahesh Gupta
	• Posterior compartment dissection with common Iliac & ureteric dissection.
	• Avascular spaces of pelvis.
	(d) Bladder & Intestinal injury repair - Dr. Kaushik Shah (Surgeon)
2.00 pm onwards	Lunch

◆ Two Credit Points allotted by GMC for this workshop ◆



Venue: Hotel St Lurn,
Ashram Road, Ahmedabad.

Date : 26th June 2013, Wednesday

Co-ordinators : Dr. Raj Iyenger,
Dr. Dhaval Shah

Chairpersons : Dr. Vijay Shah,
Dr. Harshad Shah

Program Details

Time	Subject
08.30 pm to 08.50 pm	Oral Care in Pregnancy - Dr. Cherry Mishra (Dental Student)
08.50 pm to 09.10 pm	Assessment of first trimester markers - Dr. B. I. Patel
09.10 pm to 09.30 pm	PPH - Dr. Kanan Yelikar (Aurangabad)
09.30 pm to 09.50 pm	Measurement of Nuchal Translucency; Why, When & How ? - Dr. J. P. Shah
09.50 pm to 10.10 pm	PCPNDT Act - Recent updates - Dr. Nilam Patel (CDHO)
10.10 pm to 10.30 pm	HCG regression curve :
	Key to managing GTN - Dr. Ava Desai
10.30 pm onwards	Dinner

◆ One Credit Point allotted by GMC for this program ◆

Program associates : Medley Pharma, Pulse Pharma, German Remedies (Gynova),
Svizera Healthcare, US Vitamin Ltd.



Mammography - Social Care and Cause



Mammography Screening Program has been specially designed for members of AOGS or their spouse. The program starts from July 2013.

The member should contact local Co-ordinators or the Chief Co-ordinators for their appointment; for getting mammography done.

You have the option to choose from the following :

USMANPURA IMAGING CENTRE

30, Ambica Society, Near Kalol Nagrik Bank, Opp. Usmanpura Garden, Usmanpura, Ahmedabad-380013.
Phone : 079-27552555 / 666 / 777

ACCUVIEW DIAGNOSTICS

Block-B, Neelkanth Park-II, Nr. Bsnl Telephone Exchange, Ghoda Camp Road, Shahibaug Ahmedabad-380004.
Phone : 079-22682818

SANYA DIAGNOSTIC (RADIOLOGY)

3, Ground Floor, Shivalik Ishan, Near Reliance Petro Pump, Near C. N. Vidhyalay, Ambawadi , Ahmedabad-380015.
Phone : 079-26401704/05, 40306615

SIDDHIVINAYAK IMAGING CENTER

Siddhivinayak Hospital, Behind Kakariya Lake, Maninagar, Ahmedabad-380008.
Phone : 09327052659, 079-25451821

DR. SONAL PANCHAL NAGORIS INSTITUTE OF INFERTILITY

1st Floor, Kedar Building, Opp. Krupa Petrol Pump, Nr. Parimal Garden, Ahmedabad-380006.
Phone : 079- 26401090, 26402090

DR. GHANSHYAM DABHI

Shivam X ray Clinic, Opp. Mehsana Society, Nava vadaj, Ahmedabad-380013.

AOGS will bear the expenditures of Mammography.

CHIEF CO-ORDINATORS

- Dr. Anjana Chauhan
+91 9327064981

- Dr. J. D. Patel
+91 9825037891

Co-ordinators Mobile List

Name	Number
Dr. Shital Agrawat (Vaidya)	9478600929
Dr. Shashikala Sahu	9824277494
Dr. Suvarnaben	9825233616
Dr. Krupa Trivedi	9898468038
Dr. Lalita Kothari	9228418797
Dr. Nidhi Saxena	9327115420
Dr. Kokila Patel	9427711575
Dr. Jayshree Sheth	9879791640

Name	Number
Dr. Shilpa Gajjar	9824045703
Dr. Anila Kapadia	9824039227
Dr. Neeru Shah	9327049323
Dr. Lata Trivedi	9925042824
Dr. Bina Patel	9327031131
Dr. Bela Patel	9825160599
Dr. Neeta Mishra	9924330277

The report will be delivered at AOGS. The copy of report can be obtained from AOGS office after a week, of the date of Screening.



President's Pet Project (Surgical Workshop)

The first regional Surgical Workshop was conducted on 19th May, 2013, Sunday, at Anand Multispeciality Hospital, (**Dr. Mukesh Patel**) Bapunagar.

The active team of AOGS congratulates both the co-ordinators, Dr. Mukesh Savalia & Dr. Mukesh Patel along with their team, for working very hard to make this workshop a big success.

Inauguration was done by dignitaries like Dr. Bakul Leuva, Dr. Mahesh Gupta, Dr. Dilip Gadhavi & Dr. Anil Mehta.

The conference was attended by thirty five delegates from Naroda area. Total five surgeries were performed and relayed live in the auditorium.

Two way audio video transmissions, was a very effective means of communication.

Extensive discussion continued between the audience & operating surgeon & lots of practical tips were given by the surgeons, which were appreciated by all the delegates.

Nondescent vaginal hysterectomy & Vaginal hysterectomy were demonstrated by **Dr. Vyomesh Shah** (A renowned Vaginal Surgeon from Gujarat)

Dr. Mahesh Gupta demonstrated LSCS by Misgav Ladach technique & procedures for tackling PPH, like uterine artery ligation, Internal Iliac artery Ligation, B-lynch techniques were shown.

Dr. Kaushik Vyas demonstrated Internal Iliac Artery Ligation in previous two LSCS case.

Dr. Anil Mehta demonstrated Total Lap Hysterectomy.

AOGS active team once again congratulates the first regional workshop for a grand success.

We wish them good luck for their future endeavours.

It added a lot of confidence in the delegates & the main purpose of this workshop is to sharpen the skills & the procedures look user friendly to the delegates so that in most of the cases of emergency, the situation can be tackled without getting panicked.

We have initiated this program as a regular feature where the faculty will demonstrate those procedures which are not a part of regular teaching during the post graduation.

We request the members to organise this kind of surgical workshop at their hospital, with all kind of assistance from AOGS.



Family Program
on
Sunday, 7th July 2013
6.00 pm onwards

Venue
Prakash High School, Nr. Sandesh Press,
Bodakdev, Ahmedabad.

Bumper Housie

at 6.00 pm

Dinner : 8.30 pm.

Prizes of more than
Rs. 1 lakh to be won.



Member Corner

Congratulations Dr. Mahesh Gupta & Dr. Phagun Shah.

Keep up the good work

- Dr. Sujata Mishra (Cuttack) & Dr. Roza Olyai (Gwalior)

Nice and different outlook of AOGS bulletin Congratulations

- Dr. Manish Banker (Ahmedabad)

ડૉ. મહેશ ગુપ્તા અને ડૉ. ફાગુન શાહ સહિત AOGS ની નવી કમિટીના સભ્યોએ ખૂબ ખૂબ અભિનંદન AOGS બુલેટીન નું નવુ રૂપ ખૂબ આકર્ષક છે.

- ડૉ. શિરીષ નાયક (અમદાવાદ)

Midterm SOGOG Conference

is hosted by

Ahmedabad OBGYN Society & is to be held at Udaipur.

Venue : Hotel Sheraton (5 Star)

Date : 3rd & 4th August, 2013

Conference Reg. fees

Rs. 3000/- only

[If include Reg. fees (+)
accommodation (+) all meals]

Reg. fees

accompanying person

Rs. 2500/- only

[It includes
accommodation + All meals]

**Children below
five years : free**

Children above five years :
Accompanying person
charges will apply.

* All charges are "Ex Udaipur" charges - Hurry up to avoid disappointment.

For more details contact

Dr. Mahesh Gupta

President AOGS

+91 94264 99922

Dr. Phagun Shah

Secretary AOGS

+91 98254 31233

Detail program will follow soon.

AOGS office : 079-26586426

★ ★ ★ Important Announcement ★ ★ ★

Dear Members,

Requesting you to please forward the names of your kids who have passed the board exams of Std Xth or XIIth this year.

Please send a photocopy of the marksheet along with the details.

Send the details at AOGS office or AOGS website, in next fifteen days.



The Gujarat Government Gazette

EXTRAORDINARY
PUBLISHES BY AUTHORITY

Vol. LIII Wednesday, April 11, 2012/CAITRA 22, 1934

- The Gujarat Govt. has Passed a bill to prohibit violence against medicare service persons and damage or loss of property in medicare service institutions and for the matters connected therewith and incidental thereto.
- This Act may be called the Gujarat Medicare Service Persons and Medicare Service Institutions (Presentation of Violence and Damage or Loss of Property) Act, 2012.
- Medicare service persons" in relation to a medicare service institution shall include, -
 - (I) Registered Medical Practitioners (including a person having provisional registration) working in a medicare service institution;
 - (ii) Nurses registered under the Gujarat Nurses, Midwives and Health Visitors Act, 1968;
 - (iii) Auxiliary Nurse and Mid-wife;
 - (iv) Trained Dai;
 - (v) Medical student;
 - (vi) Nursing student;
 - (vii) Para Medical staff and other staff or employee directly or indirectly employed by a medicare service institution for providing required services
- On receipt of a complaint of an act of violence to Medicare Service persons working in the Medicare Service Institution and damage or loss of Property to Medicare Service persons working in the Medicare Service Institution and damage or loss of Property to Medicare Service Institution, the Competent Authority shall prepare a report in "Form 1" and submit the same to the District Magistrate and forward a copy thereof to the police officer in charge of the police station having the jurisdiction under which the offence is committed.

For further details please visit AOGS website.

Global Consensus Statement on Menopausal Hormone Therapy

T. J. de Villiers , M. L. S. Gass * , C. J. Haines † , J. E. Hall ‡ , R. A. Lobo * * , D. D. Pierroz † † and M. Rees ‡ ‡

MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa; * Department of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA; † Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR; ‡ Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; * * Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA; † † University of Geneva, Switzerland; ‡ ‡ Reader Emeritus, University of Oxford, UK

The following Consensus Statement is endorsed by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society.

The past 10 years saw much confusion regarding the use of menopausal hormone therapy (MHT). New evidence challenged previously accepted clinical guidelines, especially on aspects of safety and disease prevention. This led to many women unnecessarily being denied the use of MHT. Detailed revised guidelines were published and regularly updated by the major regional menopause societies. The confusion was initially escalated by significant differences amongst published guidelines. In recent revisions, the differences have become much less. In view of this, The International Menopause Society took the initiative to arrange around-table discussion, in November 2012, between representatives of the major regional menopause societies to reach consensus on core recommendations regarding MHT. The aim was to produce a short document in bullet-point style, only containing the points of consensus. It is acknowledged that, in view of the global variance of disease and regulatory restrictions, these core recommendations do not replace the more detailed and fully referenced recommendations prepared by individual national and regional societies. This document serves to emphasize international consensus regarding MHT and is aimed at empowering women and healthcare practitioners in the appropriate use of MHT.

- MHT is the most effective treatment for vasomotor symptoms associated with menopause at any age, but benefits are more likely to outweigh risks for symptomatic women before the age of 60 years or within 10 years after menopause.
- MHT is effective and appropriate for the prevention of osteoporosis-related fractures in at-risk women before age 60 years or within 10 years after menopause.
- Randomized clinical trials and observational data as well as meta-analyses provide evidence that standard-dose estrogen-alone MHT may decrease coronary heart disease and all-cause mortality in women younger than 60 years of age and within 10 years of menopause. Data on estrogen plus progestogen MHT in this population show a similar trend for mortality but in most randomized clinical trials no significant increase or decrease in coronary heart disease has been found.
- Local low-dose estrogen therapy is preferred for women whose symptoms are limited to vaginal dryness or associated discomfort with intercourse.
- Estrogen as a single systemic agent is appropriate in women after hysterectomy but additional progestogen is required in the

This Statement is being simultaneously published in the journals *Climacteric* and *Maturitas* , on behalf of the International Menopause Society and The European Menopause and Andropause Society, respectively.

Correspondence: T. J. de Villiers, MediClinic Panorama, Parow 7500, South Africa

© 2013 International Menopause Society and Elsevier Inc.
DOI: 10.3109/13697137.2013.771520

- presence of a uterus.
- The option of MHT is an individual decision in terms of quality of life and health priorities as well as personal risk factors such as age, time since menopause and the risk of venous thromboembolism, stroke, ischemic heart disease and breast cancer.
- The risk of venous thromboembolism and ischemic stroke increases with oral MHT but the absolute risk is rare below age 60 years. Observational studies point to a lower risk with transdermal therapy.
- The risk of breast cancer in women over 50 years associated with MHT is a complex issue. The increased risk of breast cancer is primarily associated with the addition of a progestogen to

estrogen therapy and related to the duration of use. The risk of breast cancer attributable to MHT is small and the risk decreases after treatment is stopped.

- The dose and duration of MHT should be consistent with treatment goals and safety issues and should be individualized.
- In women with premature ovarian insufficiency, systemic MHT is recommended at least until the average age of the natural menopause.
- The use of custom-compounded bioidentical hormone therapy is not recommended.
- Current safety data do not support the use of MHT in breast cancer survivors.

These core recommendations will be reviewed in the future as new evidence becomes available.

Authors/members of the Consensus Panel

The International Menopause Society: Tobie J. de Villiers, President (MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa); David F. Archer, Treasurer (Jones Institute, Eastern Virginia Medical School, Norfolk, VA, USA); Rodney J. Baber, General Secretary (Sydney Medical School, The University of Sydney, NSW, Australia); Mary Ann Lumsden, Board member (Reproductive & Maternal Medicine, School of Medicine, University of Glasgow, Glasgow, UK); Amos Pines, Director of Education and Development (Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel); The Asia Pacific Menopause Federation: Christopher J. Haines, Honorary Secretary (Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR); The American Society

for Reproductive Medicine: Rogerio A. Lobo, Past President (Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA); The International Osteoporosis Foundation: Dominique D. Pierroz, Science Manager (University of Geneva, Switzerland); The European Menopause and Andropause Society: Margaret Rees, President (Reader Emeritus, University of Oxford, UK); Florence Tremollières, Board member (Centre de Menopause, Hopital Paule de Viguier, Toulouse, France); The Endocrine Society: Janet E. Hall, Past President (Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA); The North American Menopause Society: Margery L. S. Gass, Executive Director (Department of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA).

This Statement is being simultaneously published in the journals *Climacteric* and *Maturitas*, on behalf of the International Menopause Society and The European Menopause and Andropause Society, respectively.

Correspondence: T. J. de Villiers, MediClinic Panorama, Parow 7500, South Africa

© 2013 International Menopause Society and Elsevier Inc.
DOI: 10.3109/13697137.2013.771520

For the use of a Registered Medical Practitioner, Hospital or Laboratory only

Comprehensive approach in management of
• Threatened Miscarriage • Recurrent Miscarriage • Infertility

Rx
Duphaston^{*}
Dydrogesterone Tablet BP 10mg

- ✓ Derived from **Natural Diosgenin**¹
- ✓ **Orally effective**² unlike micronised progesterone³
- ✓ Has been used in approximately **10 million pregnancies** between 1977 and 2005⁴



1. Nature's Own
2. Duphaston AD and Mestranol (2005) 1(2) 124-128
3. Lenzini G, Nappi RE, Altieri M, et al. Progesterone
4. Duphaston AD and Mestranol (2005) 1(2) 124-128

Composition: Each scored film coated tablet contains 10 mg of dydrogesterone. **Indications:** Hormone Replacement Therapy, To counteract effects of unopposed estrogen on endometrium for women with disorders due to menopause & with intact uterus. Progesterone deficiencies in dysmenorrhoea, endometriosis, secondary amenorrhoea, irregular cycles, dysfunctional uterine bleeding, pre-menstrual syndrome, threatened and habitual abortion, infertility due to luteal insufficiency. **Dosage and Administration:** Hormone replacement therapy: in combination with continuous oestrogen therapy, 10 mg dydrogesterone daily during 14 consecutive days per cycle of 28 days. In combination with cyclical oestrogen therapy, 10 mg dydrogesterone daily during last 12-14 days of oestrogen therapy. If endometrial biopsies or ultrasound would reveal inadequate progesterational response, 20 mg dydrogesterone should be prescribed. 2. Dysmenorrhoea: 10 mg twice daily from day 5 to day 25 of cycle. 3. Endometriosis: 10 mg two or three times daily from day 5 to day 25 of cycle or continuously. 4. Premenstrual syndrome: 10 mg twice daily from day 11 to day 25 of cycle. 5. Irregular cycles: 10 mg twice daily from day 11 to day 25 of cycle. 6. Threatened abortion: 40 mg at once, then 10 mg every eight hours until symptoms remit. 7. Habitual abortion: 10 mg twice daily until twentieth week of pregnancy. 8. Infertility due to luteal insufficiency: 10 mg daily from day 14 to 25 of cycle. Treatment for at least six cycles. Advisable to continue treatment for first few months of pregnancy as described under 'habitual abortion'. **Contraindications:** Hypersensitivity, Unknown vaginal bleeding. If used to prevent endometrial hyperplasia in (women using estrogen). **Precautions:** Breakthrough bleeding, can be prevented by increasing dosage. **Interactions:** None known. **Pregnancy and lactation:** No evidence that can not be used during pregnancy. Excreted in milk of nursing mothers. Effect on ability to drive and use machines: No effect. **Undesirable effects:** Breakthrough bleeding, alterations in liver function may occur. **Pharmacodynamics:** orally active progestogen producing complete secretory endometrium in oestrogen primed uterus. **Shelf life:** 3 years **Storage:** Store in cool and dry place. **Packaging:** Blister strip of aluminium foil and PVC film, of 10 film coated tablets. **Issued on:** Jan 2010

Further information available on request from
Registered Office:
Abbott India Limited
3-4 Corporate Park, Sion Trombay Road, Mumbai - 400 071
www.abott.co.in
Copyright © 2011 Abbott. All rights reserved.
* Registered Trademark of Abbott Group of Companies
DUPH-0413-0012-B-1.1

Abbott
A Promise for Life

LPD, Threatened
Abortion, Pre-term
Labour, Recurrent
Miscarriage

Susten

(Natural Micronised Progesterone)

Delivers, Sustains, Nurtures Pregnancy... Naturally



Male
infertility
management

FERTISURE M

Astaxanthin + L-Carnitine + Co Q 10 + Lycopene + Zinc

Always Ahead

Controls ROS,
Improves sperm
parameters

Female
infertility
management

FERTISURE F

Add surety.

Reduces ROS,
Revives fertility
in females.



Who copyrighted the copyright symbol..?

herNMP

Natural Micronized Progesterone 200mg, 100mg Softgel Caps / 100mg Inj.

Her choice of Quality **Progesterone**

Sevista

Ormeloxifene 60 mg Tab

A new vista in **DUB** management

XAMIC 500

Tranexamic acid 500mg tab / 500mg inj.

Controls **Bleeding...effectively**

XAMIC MF

Tranexamic acid 500 mg + Mefenamic acid 250 mg Tab

Controls **Heavy Bleeding & Pain...effectively**

sensa 

In history of spontaneous abortions & high risk pregnancies

FOL-XTTM

5-Methyltetrahydrofolate 1mg + Methylcobalamin 1500mcg + Pyridoxine 30mg Tablets

XTRA Surety



Reduces risk of spontaneous abortion¹

Prevents development of gestational diabetes & hypertension²

Minimizes chances of sub-fertility³

Improves oocyte development & estrogen levels⁴

With Active Folate

5-MTHF



Dose: 1 Tablet Daily

References:

1. Reproductive Biology and Endocrinology 2004;2:7-14. 2. Am J Epidemiol. 2002;156:806-812. 3. Fertility and Sterility 2010;94(1):130-137. 4. Diabetes Care 1998;21(7):1017-1021.

*Helpline service available from Monday to Friday between 8 am to 7 pm

1800 103 0404

Just Dial, Toll Free from Landline or Mobile

For more information, visit

www.zydusnutriva.com

Zydus
nutriva

Zydus
nutriva

A division of Cadila Healthcare Ltd.

Zydus Tower[®] Satellite Cross Roads, Ahmedabad 380 015, India. Phone : +91-79-266 66 100 (20 Lines)
Fax : +91-79-266 66 149 www.zyduscadila.com

Emcure®

Orofer^{XT} Tablets



Ferrous Ascorbate equivalent to 100 mg elemental iron + Folic Acid 1.1 mg

Maximises Hb Levels in The shortest Possible Time!

The No.1 Oral Iron in India

- Emcure, **1st** to research and commercialize Ferrous Ascorbate
- **7 years** of active anaemia management
- Anaemia management programs for all age groups being conducted under **FESR, FOGSI-EMCURE** social responsibility



The most efficient, technologically advanced and trusted IVF group in India in partnership with IVI, Spain



Key Differentiators

- Results matching international standards
- Evidence -based practice
- World-class training and research facility
- Highest standards of ethics
- Better patient satisfaction
- Cost-effective treatment

Services Offered

- IUI • IVF • ICSI
- Frozen Embryo transfer
- Vitrification / cryopreservation of sperms, Oocyte & Embryos
- Assisted hatching
- Sperm, Ovum & Embryo donation
- Surrogacy

Advance Technology

- IMSI (Intracytoplasmic Morphologically- Selected Sperm Injection)
- Embryoscope
- PGD (Preimplantation Genetic Diagnosis)
- CGH (Comparative Genomic Hybridization Analysis of all chromosomes in embryo).
- ERA(Endometrial Receptivity Assay)

Ahmedabad | Bengaluru | Chennai | Delhi | Kolkata | Mumbai



• Infertility and Gynecological Endoscopy • Fetal medicine • Menopause

Directors - Dr. Pravin Patel | Dr. Manish Banker



**Nova IVI Fertility,
Pulse Women's Hospital Pvt. Ltd.**

108, Swastik Society, Navrangpura, Ahmedabad- 380009. T: +91 79 26422626 F: +91 79 26422616
E: ahmedabad@novaivifertility.com, mivfg@yahoo.com W: www.novaivifertility.com, www.pulse-hospital.com